| Drug General Information |
| Drug ID |
D05FFB
|
| Former ID |
DNC005818
|
| Drug Name |
5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H14N2O
|
| Canonical SMILES |
CC1=C2C(=C(C3=C1C=CN=C3)C)C4=C(N2)C=CC(=C4)O
|
| InChI |
1S/C17H14N2O/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17/h3-8,19-20H,1-2H3
|
| InChIKey |
QZTWUDDGLIDXSE-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Alpha platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| FGF-3 receptor |
Target Info |
Inhibitor |
[1]
|
| Mast/stem cell growth factor receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesion
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Bladder cancer
|
|
Central carbon metabolism in cancerhsa04014:Ras signaling pathway
|
|
Hematopoietic cell lineage
|
|
Melanogenesis
|
|
Acute myeloid leukemia
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling PathwayNetPath_15:IL3 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
KitReceptor Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
PDGF signaling pathwayP00021:FGF signaling pathway
|
|
Pathway Interaction Database
|
ATF-2 transcription factor network
|
|
PDGFR-alpha signaling pathway
|
|
PDGF receptor signaling networkcmyb_pathway:C-MYB transcription factor network
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
Reactome
|
PIP3 activates AKT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascadeR-HSA-2033514:FGFR3 mutant receptor activationR-HSA-1257604:PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Osteoblast Signaling
|
|
Focal Adhesion
|
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
|
PIP3 activates AKT signaling
|
|
Cardiac Progenitor Differentiation
|
|
Integrated Pancreatic Cancer Pathway
|
|
Allograft Rejection
|
|
Signaling Pathways in Glioblastoma
|
|
Signaling by PDGF
|
|
AngiogenesisWP51:Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
Bladder Cancer
|
|
Neural Crest Differentiation
|
|
Signaling by FGFRWP304:Kit receptor signaling pathway
|
|
Differentiation Pathway
|
|
Signaling by SCF-KIT
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
| References |
| REF 1 | J Med Chem. 2005 Oct 6;48(20):6194-201.Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. |
|---|
